+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Cancer Diagnostics Market by Diagnostic Type (Biopsy, Blood Chemistry Tests, Imaging Tests), Indication (Bladder Cancer, Blood Cancer, Breast Cancer), Components, End-Use - Forecast 2024-2030- Product Image
Global Cancer Diagnostics Market by Diagnostic Type (Biopsy, Blood Chemistry Tests, Imaging Tests), Indication (Bladder Cancer, Blood Cancer, Breast Cancer), Components, End-Use - Forecast 2024-2030- Product Image
Sale

Global Cancer Diagnostics Market by Diagnostic Type (Biopsy, Blood Chemistry Tests, Imaging Tests), Indication (Bladder Cancer, Blood Cancer, Breast Cancer), Components, End-Use - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4896788
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Diagnostics Market size was estimated at USD 29.95 billion in 2023, USD 33.31 billion in 2024, and is expected to grow at a CAGR of 11.71% to reach USD 65.06 billion by 2030.

Cancer diagnostics focus on detecting symptomatic patients to provide the best possible treatment immediately. There are multiple imaging tests available for cancer diagnosis, such as a computerized tomography (CT) scan, bone scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, ultrasound, and X-ray. The growing prevalence of cancer, significant government involvement, and favorable reimbursement policies have enhanced the adoption rate of cancer diagnostics. However, the false and inadequate results and associated high costs may hamper the market growth. Nevertheless, the ongoing advancements in cancer diagnosis equipment and integration of advanced technologies may overcome the challenge and expand the market scope in the forecast period.

Regional Insights

The American cancer diagnostics market is highly developed due to the notable prevalence of cancer and the presence of multiple advanced imaging technologies in the region. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer diagnosis. Additionally, the growing geriatric population, ongoing cancer-related research activities, and the rising burden of different types of cancer have enhanced the need for cancer diagnosis in Germany, New Zealand, the United Kingdom, and several other European nations. Moreover, the significant involvement of the European government in cancer detection and diagnosis programs has elevated the market scope. In the Asia-Pacific region, China and India are the most prevalent regions for the increasing cases of cancer patients, which has raised the need for cancer diagnostics. Furthermore, the emerging campaigns and cancer awareness programs have highlighted the need for cancer diagnostics in Asian countries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson & Company, Bio-Techne Corporation, bioMérieux SA, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Myriad Genetics, Natera, Inc., Perkin Elmer, Inc., Personal Genome Diagnostics Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc.

Market Segmentation & Coverage

This research report categorizes the Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Diagnostic Type
    • Biopsy
    • Blood Chemistry Tests
      • Complete Blood Count (CBC)
      • Cytogenetic Analysis
      • Immunophenotyping
      • Liquid Biopsy
      • Sputum Cytology
      • Tumor Marker Tests
      • Urine Cytology
    • Imaging Tests
      • Bone Scan
      • CT-Scan
      • Magnetic Resonance Imaging (MRI)
      • Nuclear Scan
      • Positron Emission Tomography (PET) Scan
      • Ultrasound
      • X-Rays
  • Indication
    • Bladder Cancer
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Kidney Cancer
    • Liver Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Skin Cancer
  • Components
    • Consumables
    • Instruments
    • Software
  • End-Use
    • Diagnostic Laboratories
    • Hospitals
    • Research Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Cancer Diagnostics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Diagnostics Market?
  3. What are the technology trends and regulatory frameworks in the Cancer Diagnostics Market?
  4. What is the market share of the leading vendors in the Cancer Diagnostics Market?
  5. Which modes and strategic moves are suitable for entering the Cancer Diagnostics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Diagnostics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing burden of cancer among younger and geriatric population
5.1.1.2. Rising government initiatives and campaigns for cancer awareness
5.1.1.3. Favorable reimbursement framework for cancer diagnosis
5.1.2. Restraints
5.1.2.1. Associated high cost of cancer diagnostic equipment and lack of oncologists
5.1.3. Opportunities
5.1.3.1. Deployement of innovative tools for cancer screening, detection, and diagnostics
5.1.3.2. Integration of nanotechnology and nanomaterials in cancer diagnosis
5.1.4. Challenges
5.1.4.1. Inadequate and false results of cancer diagnostics
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cancer Diagnostics Market, by Diagnostic Type
6.1. Introduction
6.2. Biopsy
6.3. Blood Chemistry Tests
6.4.1. Complete Blood Count (CBC)
6.4.2. Cytogenetic Analysis
6.4.3. Immunophenotyping
6.4.4. Liquid Biopsy
6.4.5. Sputum Cytology
6.4.6. Tumor Marker Tests
6.4.7. Urine Cytology
6.4. Imaging Tests
6.5.1. Bone Scan
6.5.2. CT-Scan
6.5.3. Magnetic Resonance Imaging (MRI)
6.5.4. Nuclear Scan
6.5.5. Positron Emission Tomography (PET) Scan
6.5.6. Ultrasound
6.5.7. X-Rays
7. Cancer Diagnostics Market, by Indication
7.1. Introduction
7.2. Bladder Cancer
7.3. Blood Cancer
7.4. Breast Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Pancreatic Cancer
7.10. Prostate Cancer
7.11. Skin Cancer
8. Cancer Diagnostics Market, by Components
8.1. Introduction
8.2. Consumables
8.3. Instruments
8.4. Software
9. Cancer Diagnostics Market, by End-Use
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals
9.4. Research Centers
10. Americas Cancer Diagnostics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cancer Diagnostics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cancer Diagnostics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Biocare Medical Acquires Empire Genomics
13.3.1.2. Thermo Fisher ties up $2.6B deal for The Binding Site
13.3.1.3. BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
13.3.1.4. Becton Dickinson Acquires Spanish Clinical Flow Cytometry Firm Cytognos
13.3.1.5. Cancer Diagnostics, Inc. Acquires Anatech, Ltd.
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
13.3.2.2. Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment
13.3.2.3. Fujifilm India partners with Soorya Diagnostics LLP to launch CT Scan in Tirur
13.3.2.4. EarlySign Announces Strategic Agreement to Commercialize AI Solution for Early Detection of Cancer
13.3.3. New Product Launch & Enhancement
13.3.3.1. Ibex Medical launches Galen 3.0 cancer diagnostics platform
13.3.3.2. Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
13.3.4. Investment & Funding
13.3.4.1. New Funding to underpin development of Early Stage Cancer Platform Labmate Online
13.3.4.2. Cancer diagnostics company GenoME Diagnostics bags £1.4M funding
13.3.4.3. Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers
13.3.5. Award, Recognition, & Expansion
13.3.5.1. Ibex's Galen Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR
13.3.5.2. Karkinos Healthcare launches ‘Advanced Centre For Cancer Diagnostics and Research'
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Adaptive Biotechnologies Corporation
14.1.3. Agilent Technologies, Inc.
14.1.4. Becton, Dickinson & Company
14.1.5. Bio-Techne Corporation
14.1.6. bioMérieux SA
14.1.7. Castle Biosciences Inc.
14.1.8. Danaher Corporation
14.1.9. Exact Sciences Corporation
14.1.10. F. Hoffmann-La Roche Ltd.
14.1.11. GE Healthcare
14.1.12. Hologic Inc.
14.1.13. Illumina, Inc.
14.1.14. Johnson & Johnson Services, Inc.
14.1.15. Konica Minolta, Inc.
14.1.16. Koninklijke Philips N.V.
14.1.17. Myriad Genetics
14.1.18. Natera, Inc.
14.1.19. Perkin Elmer, Inc.
14.1.20. Personal Genome Diagnostics Inc.
14.1.21. Qiagen N.V.
14.1.22. Quest Diagnostics
14.1.23. Siemens Healthineers AG
14.1.24. Sysmex Corporation
14.1.25. Thermo Fisher Scientific, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER DIAGNOSTICS MARKET DYNAMICS
FIGURE 7. CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2030 (%)
FIGURE 8. CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
FIGURE 12. CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 14. CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 6. CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 9. CANCER DIAGNOSTICS MARKET SIZE, BY COMPLETE BLOOD COUNT (CBC), BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CANCER DIAGNOSTICS MARKET SIZE, BY CYTOGENETIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CANCER DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CANCER DIAGNOSTICS MARKET SIZE, BY SPUTUM CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR MARKER TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CANCER DIAGNOSTICS MARKET SIZE, BY URINE CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 18. CANCER DIAGNOSTICS MARKET SIZE, BY BONE SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CANCER DIAGNOSTICS MARKET SIZE, BY CT-SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2030 (USD MILLION)
TABLE 21. CANCER DIAGNOSTICS MARKET SIZE, BY NUCLEAR SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. CANCER DIAGNOSTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 37. CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 41. CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 63. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 65. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 66. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 68. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 95. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 96. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 97. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 98. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 100. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 101. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 102. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 103. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 104. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 106. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 113. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 114. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 115. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 116. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 118. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 125. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 131. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 132. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 137. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 138. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 139. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 143. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 144. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 145. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 146. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 149. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 150. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 151. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 152. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 154. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 155. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 156. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 157. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 158. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 160. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 168. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 169. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 173. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 174. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 175. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 176. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 177. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 179. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 180. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 181. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 182. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 183. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 185. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 186. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 187. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 188. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 189. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 191. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 192. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 193. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 194. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 195. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 197. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 198. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 199. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 200. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 201. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 204. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 205. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 206. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 207. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 209. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 211. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 212. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 213. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 214. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 215. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 221. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 222. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 223. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 224. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 225. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 227. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 228. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 229. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 230. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 231. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 232. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 233. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 234. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 235. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 236. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 237. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 239. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 258. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 259. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 260. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 261. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 263. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 264. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 265. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 270. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 271. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 272. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 273. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 274. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 275. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 276. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 277. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 278. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 279. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 281. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 288. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 290. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 294. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 295. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 296. CANCER DIAGNOSTICS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • Becton, Dickinson & Company
  • Bio-Techne Corporation
  • bioMérieux SA
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips N.V.
  • Myriad Genetics
  • Natera, Inc.
  • Perkin Elmer, Inc.
  • Personal Genome Diagnostics Inc.
  • Qiagen N.V.
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 33.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 65.06 Billion
Compound Annual Growth Rate11.7%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Global Ovarian Cancer Diagnostics Market by Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor), Diagnosis Type (Biopsy, Blood Test, Imaging), End-User - Forecast 2024-2030 - Product Image

Global Ovarian Cancer Diagnostics Market by Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor), Diagnosis Type (Biopsy, Blood Test, Imaging), End-User - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
Global Breast Cancer Diagnostics Market by Technique (Imaging, Molecular Testing, Tissue Biopsy Tests), Cancer Type (BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer), Component, Diagnostic Type, End-User - Forecast 2024-2030 - Product Image

Global Breast Cancer Diagnostics Market by Technique (Imaging, Molecular Testing, Tissue Biopsy Tests), Cancer Type (BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer), Component, Diagnostic Type, End-User - Forecast 2024-2030

  • Report
  • 180 Pages
  • Global
From
Pancreatic Cancer Diagnostic Market Size, Share & Trends Analysis Report By Product, By Test Type (Imaging Test, Biopsy, Blood Test, Others), By Cancer Type (Exocrine, Endocrine), By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Pancreatic Cancer Diagnostic Market Size, Share & Trends Analysis Report By Product, By Test Type (Imaging Test, Biopsy, Blood Test, Others), By Cancer Type (Exocrine, Endocrine), By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 150 Pages
  • Global
From
Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 190 Pages
  • Global
From
Lung Cancer Diagnostics Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Companies Analysis - Product Image

Lung Cancer Diagnostics Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Companies Analysis

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.